156 related articles for article (PubMed ID: 37973457)
1. Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis.
Mela Osorio MJ; Moiraghi B; Osycka MV; Pavlovsky MA; Varela AI; Bendek Del Prete GE; Tosin MF; Pérez MA; Riva ME; Berrios RR; Fernández I; Sackmann Massa F; Giere I; Sighel C; Pavlovsky C
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):158-164. PubMed ID: 37973457
[TBL] [Abstract][Full Text] [Related]
2. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
Kantarjian HM; Jabbour E; Deininger M; Abruzzese E; Apperley J; Cortes J; Chuah C; DeAngelo DJ; DiPersio J; Hochhaus A; Lipton J; Nicolini FE; Pinilla-Ibarz J; Rea D; Rosti G; Rousselot P; Shah NP; Talpaz M; Srivastava S; Ren X; Mauro M
Am J Hematol; 2022 Nov; 97(11):1419-1426. PubMed ID: 36054756
[TBL] [Abstract][Full Text] [Related]
3. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia.
Haddad FG; Issa GC; Jabbour E; Yilmaz M
Expert Opin Pharmacother; 2022 May; 23(7):751-758. PubMed ID: 35412404
[TBL] [Abstract][Full Text] [Related]
4. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
5. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia.
Yang J; Surapaneni M; Schiffer CA
Expert Rev Hematol; 2022 May; 15(5):393-402. PubMed ID: 35544670
[TBL] [Abstract][Full Text] [Related]
7. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
Jabbour E; Apperley J; Cortes J; Rea D; Deininger M; Abruzzese E; Chuah C; DeAngelo DJ; Hochhaus A; Lipton JH; Mauro M; Nicolini F; Pinilla-Ibarz J; Rosti G; Rousselot P; Shah NP; Talpaz M; Vorog A; Ren X; Kantarjian H
Leukemia; 2024 Mar; 38(3):475-481. PubMed ID: 38287132
[TBL] [Abstract][Full Text] [Related]
8. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
Cortes J; Apperley J; Lomaia E; Moiraghi B; Undurraga Sutton M; Pavlovsky C; Chuah C; Sacha T; Lipton JH; Schiffer CA; McCloskey J; Hochhaus A; Rousselot P; Rosti G; de Lavallade H; Turkina A; Rojas C; Arthur CK; Maness L; Talpaz M; Mauro M; Hall T; Lu V; Srivastava S; Deininger M
Blood; 2021 Nov; 138(21):2042-2050. PubMed ID: 34407543
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
[TBL] [Abstract][Full Text] [Related]
10. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Cortes JE; Kim DW; Pinilla-Ibarz J; le Coutre PD; Paquette R; Chuah C; Nicolini FE; Apperley JF; Khoury HJ; Talpaz M; DeAngelo DJ; Abruzzese E; Rea D; Baccarani M; Müller MC; Gambacorti-Passerini C; Lustgarten S; Rivera VM; Haluska FG; Guilhot F; Deininger MW; Hochhaus A; Hughes TP; Shah NP; Kantarjian HM
Blood; 2018 Jul; 132(4):393-404. PubMed ID: 29567798
[TBL] [Abstract][Full Text] [Related]
11. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.
Jabbour EJ; Sasaki K; Haddad FG; Issa GC; Garcia-Manero G; Kadia TM; Jain N; Yilmaz M; DiNardo CD; Patel KP; Kanagal-Shamanna R; Champlin R; Khouri IF; Dellasala S; Pierce SA; Kantarjian H
Am J Hematol; 2023 Apr; 98(4):658-665. PubMed ID: 36683287
[TBL] [Abstract][Full Text] [Related]
12. The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program.
Sacha T; Szczepanek E; Dumnicka P; Góra-Tybor J; Niesiobędzka-Krężel J; Prejzner W; Wasilewska E; Kłoczko J; Ciepłuch H; Makowska W; Patkowska E; Wasilewska J; Bober G; Kopera M; Wichary R; Kroll-Balcerzak R; Gromek T; Wach M; Rudkowska-Kazanowska A; Świniarska M; Paczkowska E; Biernat M; Joks M; Oller M; Kasza R; Kostyra A; Gil J; Grzybowska-Izydorczyk O
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):405-415. PubMed ID: 34933827
[TBL] [Abstract][Full Text] [Related]
13. FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial.
Pulte ED; Chen H; Price LSL; Gudi R; Li H; Okusanya OO; Ma L; Rodriguez L; Vallejo J; Norsworthy KJ; de Claro RA; Theoret MR; Pazdur R
Oncologist; 2022 Mar; 27(2):149-157. PubMed ID: 35641211
[TBL] [Abstract][Full Text] [Related]
14. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Hoy SM
Drugs; 2014 May; 74(7):793-806. PubMed ID: 24807266
[TBL] [Abstract][Full Text] [Related]
15. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
[TBL] [Abstract][Full Text] [Related]
16. A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.
Korfi K; Mandal A; Furney SJ; Wiseman D; Somervaille TCP; Marais R
Ann Oncol; 2015 Jun; 26(6):1180-1187. PubMed ID: 25712455
[TBL] [Abstract][Full Text] [Related]
17. Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Cortes JE; Kantarjian H; Shah NP; Bixby D; Mauro MJ; Flinn I; O'Hare T; Hu S; Narasimhan NI; Rivera VM; Clackson T; Turner CD; Haluska FG; Druker BJ; Deininger MW; Talpaz M
N Engl J Med; 2012 Nov; 367(22):2075-88. PubMed ID: 23190221
[TBL] [Abstract][Full Text] [Related]
18. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE
Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926
[TBL] [Abstract][Full Text] [Related]
19. [French Chronic Myeloid Leukemia Intergroup 2022 recommendations for managing the risk of cardiovascular events on ponatinib in chronic myeloid leukemia].
Réa D; Messas E; Mirault T; Nicolini FE
Bull Cancer; 2022; 109(7-8):862-872. PubMed ID: 35725593
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
Maiti A; Franquiz MJ; Ravandi F; Cortes JE; Jabbour EJ; Sasaki K; Marx K; Daver NG; Kadia TM; Konopleva MY; Masarova L; Borthakur G; DiNardo CD; Naqvi K; Pierce S; Kantarjian HM; Short NJ
Acta Haematol; 2020; 143(6):567-573. PubMed ID: 32289808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]